Mga Batayang Estadistika
| LEI | 529900Q7IDA3WUGRZA51 |
| CIK | 1348911 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to KalVista Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 21, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| August 21, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Com |
|
| July 10, 2025 |
Subsidiaries of the Registrant. Exhibit 21.1 List of Subsidiaries of KalVista Pharmaceuticals, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization KalVista Pharmaceuticals Limited (UK) England and Wales KalVista Securities Holding Corporation Massachusetts KalVista Pharmaceuticals (Ireland) Limited Ireland KalVista Pharmaceuticals Switzerland GmbH Switzerland KalVista Pharmaceuticals Japan K.K. Japan KalVista P |
|
| July 10, 2025 |
KALVISTA PHARMACEUTICALS, INC. INSIDER TRADING POLICY As adopted March 2025 I. PURPOSE It is illegal for any employee, officer or director of KalVista Pharmaceuticals, Inc. (the “Company”) to trade in the securities of the Company while in the possession of material nonpublic information about the Company. It is also illegal for any employee, officer or director of the Company to give material non |
|
| July 10, 2025 |
Sales Agreement between the Company and TD Securities (USA) LLC, dated July 10, 2025. KALViSTA PHARMACEUTICALS, INC. $100,000,000 COMMON STOCK SALES AGREEMENT July 10, 2025 TD Securities (USA) LLC 1 Vanderbilt Avenue New York, New York 10017 Ladies and Gentlemen: KalVista Pharmaceuticals, Inc. (the “Company”), confirms its agreement (this “Agreement”) with TD Securities (USA) LLC (“TD Cowen”), as follows: 1. Issuance and Sale of Shares. The Company agrees that, from time to time du |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 10, 2025 |
Up to $100,000,000 Common Stock Table of Contents As Filed Pursuant to Rule 424(b)(5) Registration No. 333-280759 PROSPECTUS SUPPLEMENT (to Prospectus dated July 19, 2024) Up to $100,000,000 Common Stock We have entered into a sales agreement, or the sales agreement, with TD Securities (USA) LLC, or TD Cowen, relating to shares of our common stock, $0.001 par value per share, offered by this prospectus supplement. In accordance |
|
| July 10, 2025 |
Exhibit 10.23 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL License, Supply, And Distribution Agreement Between Kaken Pharmaceutical Co., Ltd. and KalVista Pharmaceuticals, Ltd. Dated April 8, 2025 TABLE OF CONTENTS Page Article 1 DEFINITIONS 5 Article 2 L |
|
| July 10, 2025 |
EX-99.1 Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year 2025 Financial Results – Received FDA approval of EKTERLY® (sebetralstat)—the first and only oral on-demand treatment for hereditary angioedema; U.S. launch underway – – Six additional global regulatory submissions under review – – Entered licensing agreements for sebetralstat commercialization in Japan and C |
|
| July 10, 2025 |
Description of Registrant’s Securities. Exhibit 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES General We are authorized to issue 105,000,000 shares of all classes of capital stock, of which 100,000,000 shares are common stock, $0.001 par value per share, and 5,000,000 shares are preferred stock, $0.001 par value per share. The following description summarizes the most important terms of our capital stock. Because it is only a summary, it d |
|
| July 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36830 KalVista Pharmaceu |
|
| July 7, 2025 |
Exhibit 99.1 KalVista Pharmaceuticals Announces FDA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema First new on-demand HAE treatment in over a decade, with potential to transform management of the disease Data demonstrated rapid symptom relief and attack resolution regardless of attack severity, location, age, or use of long-term prophylaxis, |
|
| July 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commis |
|
| July 7, 2025 |
U.S. FDA Approval of EKTERLY® (sebetralstat) July 7, 2025 Exhibit 99.2 Forward-looking statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. For this purpose, any statements that are not statements of historical fact may be deemed forwa |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commis |
|
| April 8, 2025 |
EX-99.1 Exhibit 99.1 KalVista Pharmaceuticals Enters into Licensing Agreement with Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan -Up to $24 million in upfront and milestone payments, plus royalties- -Sebetralstat has potential to become first, oral on-demand treatment of HAE in Japan, underscoring commercial opportunity- -Kaken brings regional expertise and proven track recor |
|
| April 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 12, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2025 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 12, 2025 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update –Announced seventh regulatory application submission and secured orphan drug designation for sebetralstat in Japan for hereditary angioedema– – Presented new data that showed effectiveness of sebetralstat to address critical unmet needs in laryngeal attacks, adolescents with HAE and patients |
|
| March 12, 2025 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [*], HAS BEEN OMITTED BECAUSE IT IS NOT MATERIAL AND OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE AND CONFIDENTIAL. Purchase and Sale Agreement By and Among KalVista Pharmaceuticals Limited, DRI Healthcare Acquisitions LP and, solely for the purposes of the Guarantor Provisions, KalVista Pharmaceuticals, Inc. |
|
| March 12, 2025 |
Exhibit 10.2 Dated 4 November 2024 KalVista Pharmaceuticals Limited as Company and DRI Healthcare Acquisitions LP as Purchaser DEBENTURE CREATING FIXED AND FLOATING CHARGES Slaughter and May One Bunhill Row London EC1Y 8YY CONTENTS 1. DEFINITIONS AND INTERPRETATION 1 2. PAYMENT OF SECURED OBLIGATIONS 8 3. FIXED CHARGES, ASSIGNMENTS, FLOATING CHARGE AND US SECURITY INTEREST 8 4. CRYSTALLISATION OF |
|
| February 3, 2025 |
EXHIBIT 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock of KalVista Pharmaceuticals, Inc. and further agree that this agreement be included as an exhibit to such filing. |
|
| January 16, 2025 |
As filed with the Securities and Exchange Commission on January 16, 2025 As filed with the Securities and Exchange Commission on January 16, 2025 Registration No. |
|
| January 16, 2025 |
Amended and Restated 2021 Equity Inducement Plan and forms of agreement Exhibit 99.5 KalVista Pharmaceuticals, Inc. 2021 Equity Inducement Plan (as amended and restated through January 10, 2025) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an |
|
| January 16, 2025 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(7) Equity Common stock, par val |
|
| December 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| December 16, 2024 |
KalVista Appoints Jeb Ledell as Chief Operating Officer Exhibit 99.1 KalVista Appoints Jeb Ledell as Chief Operating Officer Cambridge, MA and Salisbury, England, December 16, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Jeb Ledell has joined the Company as Chief Operating Officer (COO). Mr. Ledell is an accomplished public company COO with a track record of driving operational excellence and strategic growth within the bi |
|
| December 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 05, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| December 5, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update –Continuing to build commercial infrastructure; on track for potential sebetralstat launch in Q2 2025– –Multinational regulatory submissions for sebetralstat position Company to transform hereditary angioedema (HAE) treatment worldwide– – Pro forma cash and cash equivalents of $292.2 million |
|
| November 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| November 26, 2024 |
KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors Exhibit 99.1 KalVista Pharmaceuticals Appoints Laurence Reid, Ph.D., to Board of Directors Cambridge, Mass., and Salisbury, England, November 26, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Laurence Reid, Ph.D., has been appointed to the Company’s Board of Directors, effective immediately. Dr. Reid brings more than three decades of experience with a track record of l |
|
| November 14, 2024 |
EX-99.1 2 ex991.htm EXHIBIT 99.1 Exhibit 99.1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, the undersigned agree to the joint filing of a Statement on Schedule 13G (including any and all amendments thereto) with respect to the Common Stock, $0.001 par value per share, of KalVista Pharmaceuticals, Inc. and further agree to the fil |
|
| November 14, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d1152265213g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 14, 2024 |
JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) EX-99.1 2 p24-3216exhibit991.htm JOINT ACQUISITION STATEMENT EXHIBIT 99.1 JOINT ACQUISITION STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity |
|
| November 14, 2024 |
SC 13G 1 p24-3216sc13g.htm KALVISTA PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) September 30, 2024 (Date of event which requires filing of this st |
|
| November 14, 2024 |
SC 13G/A 1 kalv1015242sc13ga3.htm AMENDMENT NO. 3 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement |
|
| November 13, 2024 |
SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| November 12, 2024 |
SC 13G/A 1 p24-3028sc13ga.htm KALVISTA PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) September 30, 2024** (Date of Event Which Requires Filing of |
|
| November 7, 2024 |
SC 13D/A 1 d838079dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 5)* Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Ad |
|
| November 4, 2024 |
Exhibit 1.1 5,500,000 Shares of Common Stock ($0.001 par value per share) KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENT November 4, 2024 JEFFERIES LLC BOFA SECURITIES, INC. TD SECURITIES (USA) LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the Several Underwriters c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o BofA Securities, Inc. One Bryant Park New |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Co |
|
| November 4, 2024 |
Exhibit 1.2 Execution Version SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of November 4, 2024, by and among KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “Investor” and together, the “Investors”). WHEREAS, the Company and the Investors are |
|
| November 4, 2024 |
KALVISTA PHARMACEUTICALS, INC. 5,500,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-280759 PROSPECTUS SUPPLEMENT (To Prospectus dated July 19, 2024) KALVISTA PHARMACEUTICALS, INC. 5,500,000 Shares of Common Stock We are offering 5,500,000 shares of our common stock, $0.001 par value per share. An accredited investor affiliated with DRI Healthcare Trust has agreed to purchase 500,000 shares of our common stock |
|
| November 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Co |
|
| November 4, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Enters into Non-Dilutive Synthetic Royalty Financing with DRI Healthcare Trust –Provides up to $184 million investment to support commercial launch of sebetralstat which, if approved, will be the first and only oral on-demand therapy for HAE – –Strengthens financial position as KalVista establishes global footprint for expected launches in multiple geographies |
|
| November 4, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Announces Pricing of a $55 Million Underwritten Offering of Common Stock and Concurrent Private Placement of $5 Million Cambridge, MA & Salisbury, England, November 4, 2024 – KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of an underwritten offering of 5,500,000 shares of its common stock at a price of $10.00 per share t |
|
| October 4, 2024 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 03, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 10, 2024 |
Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (“Agreement”) is made and entered into on this 9th day of September, 2024 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Brian Piekos (hereinafter, the “Executive”). This Agreement supersedes and replaces any and all prior agreements between the Executive and the Company. REC |
|
| September 10, 2024 |
Exhibit 10.3 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (“Agreement”) is made and entered into on this 9th day of September, 2024 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Paul K. Audhya, MD (hereinafter, the “Executive”). RECITALS WHEREAS, the Executive is currently employed by the C |
|
| September 10, 2024 |
KalVista Appoints Brian Piekos as Chief Financial Officer Exhibit 99.1 KalVista Appoints Brian Piekos as Chief Financial Officer Cambridge, MA and Salisbury, England, September 10, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), today announced that Brian Piekos has joined the Company as Chief Financial Officer (CFO). Mr. Piekos is an experienced public company CFO who brings a demonstrated track record of successfully leading companies across the |
|
| September 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 06, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) ( |
|
| September 10, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (“Agreement”) is made and entered into on this 9th day of September, 2024 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Benjamin L. Palleiko (hereinafter, the “Executive”). RECITALS WHEREAS, the Executive is currently employed by the |
|
| September 5, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update –U.S. FDA accepts NDA for sebetralstat for oral on-demand treatment of HAE; Sets PDUFA goal date of June 17, 2025– –European Medicines Agency (EMA) validated the submission of Marketing Authorization Application (MAA) for sebetralstat– Cambridge, MA and Salisbury, England, September 5, 2024 – |
|
| September 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 5, 2024 |
Exhibit 10.1 EXECUTION VERSION LEASE AGREEMENT BY AND BETWEEN OS 990 CORPORATE CENTER ASSOCIATES LLC, a Delaware limited liability company, AS LANDLORD, AND KALVISTA PHARMACEUTICALS, INC., a Delaware corporation, AS TENANT Fifth (5ᵗʰ) and First (1ˢᵗ) Floors 200 Crossing Boulevard Framingham, Massachusetts Exhibit 10.1 TABLE OF CONTENTS Page Article 1 BASIC LEASE PROVISIONS 1 Article 2 TERM/PREMISE |
|
| September 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) ( |
|
| September 5, 2024 |
Separation Agreement by and between the Registrant and T. Andrew Crockett, dated March 6, 2024. Exhibit 10.2 March 6, 2024 VIA E-MAIL T. Andrew Crockett [***] Re: Terms of Separation Dear Andrew: This letter confirms the agreement (this “Agreement”) between you and KalVista Pharmaceuticals, Inc. (the “Company”) concerning the terms of your separation and offers you the separation compensation we discussed in exchange for a general release of claims and covenant not to sue. 1. Separation Date |
|
| August 22, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defi |
|
| July 23, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 22, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 17, 2024 |
KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 CORRESP KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 July 17, 2024 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, DC 20549 Attention: Tamika Sheppard Re: KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed July 11, 2024 File N |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 11, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 11, 2024 |
List of Subsidiaries of KalVista Pharmaceuticals, Inc. Exhibit 21.1 List of Subsidiaries of KalVista Pharmaceuticals, Inc. Name of Subsidiary Jurisdiction of Incorporation or Organization KalVista Pharmaceuticals Limited (UK) England and Wales KalVista Securities Holding Corporation Massachusetts KalVista Pharmaceuticals (Ireland) Limited Ireland KalVista Pharmaceuticals CH GmbH Switzerland KalVista Pharmaceuticals Japan K.K. Japan |
|
| July 11, 2024 |
Exhibit 97.1 KalVista Pharmaceuticals, Inc. Compensation Recovery Policy (Effective December 1, 2023) The Board has determined that it is in the best interests of the Company and its stockholders to adopt this Policy enabling the Company to recover from specified current and former Company executives certain incentive-based compensation in the event of an accounting restatement resulting from mate |
|
| July 11, 2024 |
EX-FILING FEES EXHIBIT 107 Calculation of Filing Fee Tables Form S-3 (Form Type) KalVista Pharmaceuticals, Inc. |
|
| July 11, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – Submitted NDA for sebetralstat as first-ever, oral on-demand treatment for HAE attacks, a pivotal moment for the HAE community – – Potential FDA approval and launch of sebetralstat in first half 2025 - Cambridge, MA and Salisbury, England, July 11, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KA |
|
| July 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36830 KalVista Pharmaceu |
|
| July 11, 2024 |
Exhibit 10.17# AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (“Agreement”) is made and entered into on this 7th day of March, 2024 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Benjamin L. Palleiko (hereinafter, the “Executive”). RECITALS WHEREAS, the Executive is currently employed by the C |
|
| July 11, 2024 |
EX-4.2 Exhibit 4.2 FORM OF DEBT SECURITY [Face of Security] KALVISTA PHARMACEUTICALS, INC. [If applicable, insert—FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS “PRINCIPAL AMOUNT”), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT |
|
| July 11, 2024 |
As filed with the Securities and Exchange Commission on July 11, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on July 11, 2024 Registration No. |
|
| July 11, 2024 |
EX-4.3 Exhibit 4.3 KALVISTA PHARMACEUTICALS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1—DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2—THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERI |
|
| June 28, 2024 |
Amended and Restated 2021 Equity Inducement Plan and forms of agreement Exhibit 99.1 KalVista Pharmaceuticals, Inc. 2021 Equity Inducement Plan (as amended and restated through June 20, 2024) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an op |
|
| June 28, 2024 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(4) Equity Common stock, p |
|
| June 28, 2024 |
As filed with the Securities and Exchange Commission on June 28, 2024 As filed with the Securities and Exchange Commission on June 28, 2024 Registration No. |
|
| April 22, 2024 |
KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors Exhibit 99.1 KalVista Pharmaceuticals Appoints William C. Fairey to Board of Directors Cambridge, MA and Salisbury, England, April 22, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced that William C. Fairey has been appointed to the |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| April 1, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / TCG Crossover GP I, LLC - SC 13D/A Activist Investment SC 13D/A 1 d820787dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497 10 3 (CUSIP Number) Craig Skaling Chief Financial Officer TCG Crossover GP I, LLC 705 Hi |
|
| March 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 11, 2024 |
Exhibit 4.1 KALVISTA PHARMACEUTICALS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 202[ ] KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assig |
|
| March 11, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Third Fiscal Quarter Results and Provides Operational Update - Sebetralstat Phase 3 KONFIDENT clinical trial met all endpoints and demonstrated a favorable safety profile as first oral on-demand therapy for hereditary angioedema - - CEO transition supports ongoing evolution into commercial company - Cambridge, MA and Salisbury, England, March 11, 2024 |
|
| March 11, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 7, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Announces Appointment of Benjamin L. Palleiko as Chief Executive Officer – Planned transition reflects evolution to commercial company with sebetralstat for HAE – – NDA filing remains on track for H1 2024; Europe and Japan filings H2 2024 – Cambridge, MA and Salisbury, England, March 7, 2024 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pha |
|
| March 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| February 26, 2024 |
SC 13G 1 p24-0971sc13g.htm KALVISTA PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) February 15, 2024 (Date of Event Which Requires Filing of This Sta |
|
| February 22, 2024 |
SC 13D/A 1 d759747dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 4)* Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Ad |
|
| February 20, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / TCG Crossover GP I, LLC - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497 10 3 (CUSIP Number) Craig Skaling Chief Financial Officer TCG Crossover GP I, LLC 705 High St. Palo Alto, CA 94301 (65 |
|
| February 16, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| February 16, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256378 PROSPECTUS SUPPLEMENT (To Prospectus dated June 1, 2021) KALVISTA PHARMACEUTICALS, INC. 7,016,312 Shares of Common Stock Pre-Funded Warrants to Purchase up to 3,483,688 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering 7,016,312 shares of our common stock, $0. |
|
| February 16, 2024 |
Exhibit 1.1 7,016,312 Shares of Common Stock Pre-Funded Warrants to Purchase Up to 3,483,688 Shares of Common Stock ($0.001 par value per share) KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENT February 14, 2024 JEFFERIES LLC LEERINK PARTNERS LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o Jefferies LLC 520 Madison Avenue |
|
| February 16, 2024 |
Exhibit 99.1 KalVista Pharmaceuticals Announces Pricing of a $160.1 Million Public Offering of Common Stock and Pre-Funded Warrants Cambridge, MA & Salisbury, England, February 15, 2024 – KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) (“KalVista”) today announced the pricing of its underwritten public offering of (i) 7,016,312 shares of its common stock at a price to the public of $15.25 per share |
|
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| February 14, 2024 |
SC 13G/A 1 tm246235d9sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Ch |
|
| February 14, 2024 |
SUBJECT TO COMPLETION, DATED FEBRUARY 14, 2024 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256378 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| February 14, 2024 |
Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
Exhibit 99.1 Corporate Overview February 2024 Forward-Looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that are based on our management’s beliefs and assumptions and on information currently available to our management. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quant |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2024 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| February 13, 2024 |
Exhibit 99.2 KalVista Pharmaceuticals Reports Phase 3 KONFIDENT Trial Meets All Endpoints for Sebetralstat as First Oral On-demand Therapy for Hereditary Angioedema – Sebetralstat 300 mg achieved beginning of symptom relief in 1.6 hours – – Safety profile comparable to placebo – – On track for submission of new drug application to U.S. FDA in the first half of 2024 – – Conference call to discuss t |
|
| February 13, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: KalVista Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 483497103 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1 |
|
| February 13, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 12, 2024 |
KALV / KalVista Pharmaceuticals, Inc. / Saturn V Capital Management LLC - SC 13G Passive Investment SC 13G 1 tm245941d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed |
|
| January 9, 2024 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. |
|
| January 9, 2024 |
As filed with the Securities and Exchange Commission on January 9, 2024 As filed with the Securities and Exchange Commission on January 9, 2024 Registration No. |
|
| December 28, 2023 |
SC 13G/A 1 tm2333818d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 26, 2023 (Date of Event Which Requires Filing of this Statement) C |
|
| December 14, 2023 |
SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Address and Telephone Number of |
|
| December 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| December 7, 2023 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results and Provides Operational Update - Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Targeted Number of Attacks to Complete Trial - - Data Readout on Track for Early 2024; NDA Filing Expected H1 2024 - Cambridge, MA and Salisbury, England, December 7, 2023 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical sta |
|
| December 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 07, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| December 7, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KALVISTA PHARMACEUTICALS, INC. KalVista Pharmaceuticals, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. That the name of this Co |
|
| September 28, 2023 |
Certificate of Amendment to the Amended and Restated Certificate of Incorporation. Exhibit 3.1 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF KALVISTA PHARMACEUTICALS, INC. KalVista Pharmaceuticals, Inc. (hereinafter called the “Corporation”), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), does hereby certify as follows: 1. That the name of this Co |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) ( |
|
| September 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 07, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) ( |
|
| September 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 7, 2023 |
Exhibit 99.1 KalVista Pharmaceuticals Reports First Fiscal Quarter Results and Provides Operational Update – Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout on Track for Q4 – – Preparations Continue for NDA filing H1 2024 and Rapid Commercialization Upon Approval – Cambridge, MA and Salisbury, England, September 7, 2023 –KalVista Pharmaceuticals, Inc. (NASDAQ |
|
| August 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| August 14, 2023 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
| August 4, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36830 KalVista Pharmaceu |
|
| July 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| July 10, 2023 |
Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – Sebetralstat Phase 3 KONFIDENT Clinical Trial Achieves Target Enrollment; Data Readout Expected in Q4 – – Company Funded Into 2025 With NDA Planned for H1 2024 – Cambridge, MA and Salisbury, England, July 7, 2023 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical comp |
|
| June 20, 2023 |
As filed with the Securities and Exchange Commission on June 20, 2023 As filed with the Securities and Exchange Commission on June 20, 2023 Registration No. |
|
| June 20, 2023 |
Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(3) Maximum Aggregate Offering Price(3) Fee Rate Amount of Registration Fee(4) Equity Common stock, p |
|
| June 20, 2023 |
Amended and Restated 2021 Equity Inducement Plan and forms of agreement Exhibit 99.1 KalVista Pharmaceuticals, Inc. 2021 Equity Inducement Plan (as amended and restated through June 14, 2023) 1. PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an op |
|
| June 14, 2023 |
Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (“Agreement”) is made and entered into on this 8th day of June, 2023 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Benjamin L. Palleiko (hereinafter, the “Executive”). RECITALS WHEREAS, the Executive is currently employed by the Comp |
|
| June 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 08, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 14, 2023 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF KALVISTA PHARMACEUTICALS, INC. (Formerly known as CARBYLAN THERAPEUTICS, INC.) Amended and Restated on June 14, 2023 SECTION 1 - STOCKHOLDERS Section 1.1. Annual Meeting. An annual meeting of the stockholders of KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) for the election of directors to succeed those whose term expire and f |
|
| March 10, 2023 |
KALV / KalVista Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 9, 2023 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Third Fiscal Quarter Results - Enrollment in sebetralstat KONFIDENT phase 3 trial passes 50% milestone; data remains H2 2023 - - Sebetralstat phase 2 data published in The Lancet - - Company funded into 2025 - Cambridge, MA and Salisbury, England, March 9, 2023 –KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focu |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 09, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 14, 2023 |
KALV / Kalvista Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Passive Investment SC 13G/A 1 kalv282316sc13ga1.htm AMENDMENT NO. 1 Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of This Statement) |
|
| February 14, 2023 |
KALV / Kalvista Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 4)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 14, 2023 |
KALV / Kalvista Pharmaceuticals Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2023 |
KALV / Kalvista Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment SC 13G/A 1 d992878713g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check th |
|
| February 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) December 30, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| January 31, 2023 |
KALV / Kalvista Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment kalv22a1.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 483497103 13G Page 1 of 12 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.1)* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 202 |
|
| January 10, 2023 |
As filed with the Securities and Exchange Commission on January 10, 2023 As filed with the Securities and Exchange Commission on January 10, 2023 Registration No. |
|
| January 10, 2023 |
EXHIBIT 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. |
|
| January 9, 2023 |
SC 13G 1 tm232575d1sc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 28, 2022 (Date of Event Which Requires Filing of This Statement) Check the |
|
| January 9, 2023 |
KALV / Kalvista Pharmaceuticals Inc / TCG Crossover GP I, LLC - SC 13D Activist Investment SC 13D 1 d432013dsc13d.htm SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497 10 3 (CUSIP Number) Craig Skaling Chief Financial Officer TCG Crossover GP I, LLC 705 High St. |
|
| January 9, 2023 |
EX-99.1 2 d432013dex991.htm EX-99.1 Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13D is filed on behalf of each of the undersigned, and any amendments thereto executed by the undersigned shall be filed on behalf of each of the undersigned without the necessity of filing any additional joint filing agreement. The undersigned acknowledge that |
|
| January 5, 2023 |
KalVista Pharmaceuticals Announces Benjamin L. Palleiko Promoted to President - Expanded role to lead business and commercial growth ? - Follows $58 million financing in December 2022 led by top-tier syndicate ? Cambridge, MA and Salisbury, England, January 5, 2023 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and co |
|
| January 5, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 04, 2023 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Co |
|
| December 30, 2022 |
EX-99.A 2 d402999dex99a.htm EX-99.A EXHIBIT A AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need to be filed with respect to the ownership by each of the undersigned of shares of Common Stock of Kalvista Pharmaceuticals, Inc. Date: December 30, 2022 FRAZIER L |
|
| December 30, 2022 |
SC 13D/A 1 d402999dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Kalvista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey 601 Union Street, Suite 3200 Seattle, WA 98101 Telephone: (206) 621-7200 (Name, Ad |
|
| December 27, 2022 |
EX-4.1 2 d420223dex41.htm EX-4.1 Exhibit 4.1 KALVISTA PHARMACEUTICALS, INC. FORM OF WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. [ ] Original Issue Date: [ ], 202[ ] KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowle |
|
| December 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (C |
|
| December 27, 2022 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-256378 PROSPECTUS SUPPLEMENT (To the Prospectus Dated June 1, 2021) KALVISTA PHARMACEUTICALS, INC. 9,484,199 Shares of Common Stock Pre-Funded Warrants to Purchase up to 182,470 Shares of Common Stock Pursuant to this prospectus supplement and the accompanying prospectus, we are offering directly 9,484,199 shares of our common |
|
| December 27, 2022 |
EX-10.1 4 d420223dex101.htm EX-10.1 Exhibit 10.1 FORM OF SUBSCRIPTION AGREEMENT KalVista Pharmaceuticals, Inc. 55 Cambridge Parkway Suite 901 East Cambridge, Massachusetts 02142 Ladies and Gentlemen: The undersigned (the “Investor”) hereby confirms its agreement with you as follows: 1. This Subscription Agreement (this “Agreement”) is made as of the date set forth below between KalVista Pharmaceut |
|
| December 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 08, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| December 8, 2022 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results - Phase 1 Clinical Trial for Orally Disintegrating Tablet Formulation of Sebetralstat Completed - -Sebetralstat Data Published in the Journal of Medicinal Chemistry and Xenobiotica ? - Sebetralstat Phase 3 Data Remain on Track for H2 2023 ? Cambridge, MA and Salisbury, England, December 8, 2022 ? KalVista Pharmaceuticals, |
|
| December 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| October 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 13, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Co |
|
| October 17, 2022 |
Exhibit 99.1 KalVista Pharmaceuticals Announces Appointment of Brian J.G. Pereira, M.D. as Board Chairman ? Current Board Chairman Martin Edwards, M.D. to Retire in Planned Transition - Cambridge, MA and Salisbury, England, October 17, 2022 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, |
|
| October 11, 2022 |
DEFA14A 1 d701439ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as |
|
| September 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 08, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) ( |
|
| September 8, 2022 |
Exhibit 99.1 KalVista Pharmaceuticals Reports First Fiscal Quarter Results - KVD824 Phase 2 Clinical Trial Reaches 50% Enrollment Milestone - - Open Label Extension Study Initiated for Sebetralstat - Cambridge, MA and Salisbury, England, September 8, 2022 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercializ |
|
| September 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| August 22, 2022 |
DEF 14A 1 d378074ddef14a.htm DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Com |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 15, 2022 |
KALV / Kalvista Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to design |
|
| July 7, 2022 |
Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – Sebetralstat Phase 3 KONFIDENT and KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track – – Formal Notification Received of Sebetralstat EU Orphan Drug Status – Cambridge, MA and Salisbury, England, July 7, 2022 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical |
|
| July 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36830 KalVista Pharmaceu |
|
| July 7, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 07, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 27, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Commis |
|
| May 26, 2022 |
KALV / Kalvista Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP Passive Investment Securities and Exchange Commission Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| May 18, 2022 |
KALV / Kalvista Pharmaceuticals Inc / GREAT POINT PARTNERS LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| March 10, 2022 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Third Fiscal Quarter Results ? KVD900 Phase 3 KONFIDENT Trial Initiated? ? KVD824 Phase 2 KOMPLETE Clinical Trial Enrollment on Track ? Cambridge, MA and Salisbury, England, March 10, 2022 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 10, 2022 |
As filed with the Securities and Exchange Commission on March 10, 2022 As filed with the Securities and Exchange Commission on March 10, 2022 Registration No. |
|
| March 10, 2022 |
Exhibit 107 CALCULATION OF FILING FEE TABLES Form S-8 (Form Type) KalVista Pharmaceuticals, Inc. |
|
| March 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 7, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 07, 2022 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (Comm |
|
| March 7, 2022 |
KalVista Pharmaceuticals Announces Initiation of KVD900 Phase 3 KONFIDENT Clinical Trial -KONFIDENT to Evaluate KVD900 As First Oral On-Demand Therapy for HAE- -KONFIDENT Designed to Support Broad Label for Treatment of All HAE Attacks- Cambridge, MA and Salisbury, England, March 7, 2022 ? KalVista Pharmaceuticals, Inc. |
|
| February 14, 2022 |
JOINT FILING AGREEMENT February 14, 2022 EX-99.1 2 d187129dex991.htm EX-99.1 EXHIBIT 99.1 JOINT FILING AGREEMENT February 14, 2022 Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 or Section 16 of the Act or any rule o |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to desi |
|
| February 14, 2022 |
KALV / Kalvista Pharmaceuticals Inc / EVENTIDE ASSET MANAGEMENT, LLC - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* KalVista Pharmaceuticals, Inc. (Name of Issuer ? as specified in its charter) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2022 |
KALV / Kalvista Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
KALV / Kalvista Pharmaceuticals Inc / Ikarian Capital, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to design |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 11, 2022 |
KALV / Kalvista Pharmaceuticals Inc / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 11, 2022 |
KALV / Kalvista Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2022 |
KALV / Kalvista Pharmaceuticals Inc / Longwood Fund II, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) Christoph Westphal, M.D., Ph.D. Longwood Fund Management Prudential Tower, Suite 1555 800 Boylston Street Boston, Massa |
|
| February 4, 2022 |
KALV / Kalvista Pharmaceuticals Inc / FRANKLIN RESOURCES INC Passive Investment kalv21in.htm - Generated by SEC Publisher for SEC Filing CUSIP NO. 483497103 13G Page 1 of 14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 202 |
|
| February 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to whic |
|
| January 31, 2022 |
KALV / Kalvista Pharmaceuticals Inc / Frazier Life Sciences Public Fund, L.P. Activist Investment CUSIP No. 483497103 Page 1 of 15 Pages UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Amendment No. 1 Under the Securities Exchange Act of 1934 KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 320 |
|
| December 30, 2021 |
CUSIP No. 483497103 Page 1 of 18 Pages UNITED STATES Securities and exchange commission Washington, D.C. 20549 SCHEDULE 13D Amendment No. Under the Securities Exchange Act of 1934 KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) Steve R. Bailey Frazier Healthcare Partners 601 Union Street, Suite 3200 Se |
|
| December 30, 2021 |
Kalvista Pharmaceuticals, Inc. SC 13D Exhibit 99.1 JOINT FILING agreement In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the undersigned agree to the joint filing on behalf of each of them of a Statement on Schedule 13D (including any and all amendments thereto) with respect to the common stock, par value $0.001 per share, of KalVista Pharmaceuticals, Inc., |
|
| December 9, 2021 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results ? Preparing for Initiation of KVD900 Phase 3 Clinical Trial? ? KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling ? ? Funded Beyond Data on Both HAE Trials ? Cambridge, MA and Salisbury, England, December 9, 2021 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery |
|
| December 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 09, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) (C |
|
| December 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| October 25, 2021 |
KALV / Kalvista Pharmaceuticals Inc / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| October 4, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) ( |
|
| September 17, 2021 |
KALV / Kalvista Pharmaceuticals Inc / SUVRETTA CAPITAL MANAGEMENT, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) ( |
|
| September 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (C |
|
| September 9, 2021 |
Exhibit 99.1 KalVista Pharmaceuticals Reports First Fiscal Quarter Results ? FDA End-of-Phase 2 Meeting for KVD900 Oral HAE Phase 3 Program Scheduled for This Month ? ? KVD824 Phase 2 KOMPLETE Clinical Trial Enrolling ? Cambridge, MA and Salisbury, England, September 9, 2021 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, developme |
|
| August 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| August 17, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| July 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 13, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commi |
|
| July 13, 2021 |
As filed with the Securities and Exchange Commission on July 13, 2021 As filed with the Securities and Exchange Commission on July 13, 2021 Registration No. |
|
| July 13, 2021 |
Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results ? FDA End-of-Phase 2 Meeting on KVD900 Oral HAE Phase 3 Program Scheduled for Late Q3 2021 ? ? FDA Response Submission for KVD824 Phase 2 Clinical Hold Expected Q3 2021 ? Cambridge, MA and Salisbury, England, July 13, 2021 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceuti |
|
| July 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended April 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-36830 KalVista Pharmaceu |
|
| July 13, 2021 |
2021 Equity Inducement Plan and forms of agreement Exhibit 10.21 KALVISTA PHARMACEUTICALS, INC. 2021 EQUITY INDUCEMENT PLAN 1.PURPOSE. The purpose of this Plan is to provide incentives to attract and motivate eligible employees whose potential contributions are important to the success of the Company, and any Parents, Subsidiaries and Affiliates that exist now or in the future, by offering them an opportunity to participate in the Company?s future |
|
| July 13, 2021 |
Executive Employment Agreement by and between Registrant and Dr. Paul K. Audhya, MD Exhibit 10.18 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (?Agreement?) is made and entered into on this 12th day of April, 2021 by and between KalVista Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Paul K. Audhya, MD (hereinafter, the ?Executive?). RECITALS WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by |
|
| June 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commi |
|
| June 30, 2021 |
Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF KALVISTA PHARMACEUTICALS, INC. (Formerly known as CARBYLAN THERAPEUTICS, INC.) SECTION 1 - STOCKHOLDERS Section 1.1.Annual Meeting. An annual meeting of the stockholders of KalVista Pharmaceuticals, Inc., a Delaware corporation (the ?Corporation?) for the election of directors to succeed those whose term expire and for the transaction of such other busine |
|
| June 7, 2021 |
Exhibit 99.1 KalVista Pharmaceuticals Presents Phase 2 Clinical Data of Oral KVD900 for Treatment of HAE at C1-Inhibitor Deficiency & Angioedema Workshop ? KVD900 Efficacious Within First Hours of Attack and Significantly Shortens Time to Improvement of Attack Symptoms ? Cambridge, MA and Salisbury, England, June 5, 2021 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceuti |
|
| June 7, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commis |
|
| May 27, 2021 |
KALV / Kalvista Pharmaceuticals Inc / RA CAPITAL MANAGEMENT, L.P. - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) May 24, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate th |
|
| May 27, 2021 |
KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 KALVISTA PHARMACEUTICALS, INC. 55 Cambridge Parkway Suite 901E Cambridge, Massachusetts 02142 May 27, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, DC 20549 Attention: Ada D. Sarmento Re: KalVista Pharmaceuticals, Inc. Registration Statement on Form S-3 (File No. 333-256378) filed May 21, 2021. Requested Date: June 1, |
|
| May 21, 2021 |
Exhibit 4.3 FORM OF DEBT SECURITY [Face of Security] KALVISTA PHARMACEUTICALS, INC. [If applicable, insert?FOR PURPOSES OF THE ORIGINAL ISSUE DISCOUNT PROVISIONS OF THE INTERNAL REVENUE CODE OF 1986, THE ISSUE PRICE OF THIS SECURITY IS % OF ITS PRINCIPAL AMOUNT AT STATED MATURITY SET FORTH BELOW (ITS ?PRINCIPAL AMOUNT?), THE AMOUNT OF ORIGINAL ISSUE DISCOUNT IS % OF ITS PRINCIPAL AMOUNT, THE YIELD |
|
| May 21, 2021 |
Exhibit 1.2 KalVista Pharmaceuticals, Inc. Shares of Common Stock (par value $0.001 per share) Controlled Equity OfferingSM Sales Agreement May 21, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, NY 10022 Ladies and Gentlemen: KalVista Pharmaceuticals, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cantor Fitzgerald & Co. (the “Agent”), as follo |
|
| May 21, 2021 |
As filed with the Securities and Exchange Commission on May 21, 2021 Table of Contents As filed with the Securities and Exchange Commission on May 21, 2021 Registration No. |
|
| May 21, 2021 |
Exhibit 4.4 KALVISTA PHARMACEUTICALS, INC. And , as Trustee INDENTURE Dated as of , TABLE OF CONTENTS ARTICLE 1?DEFINITIONS AND INCORPORATION BY REFERENCE 1 1.1 DEFINITIONS 1 1.2. OTHER DEFINITIONS 4 1.3. INCORPORATION BY REFERENCE OF TRUST INDENTURE ACT 4 1.4. RULES OF CONSTRUCTION 4 ARTICLE 2?THE SECURITIES 5 2.1. ISSUABLE IN SERIES 5 2.2. ESTABLISHMENT OF TERMS OF SERIES OF SECURITIES 5 2.3. EX |
|
| May 7, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| March 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2021 |
As filed with the Securities and Exchange Commission on March 11, 2021 Registration No. |
|
| March 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| March 11, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Comm |
|
| March 11, 2021 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Third Fiscal Quarter Results – Recent KVD900 Phase 2 Clinical Trial Results Statistically and Clinically Significant – – IND Submitted for Oral Prophylactic HAE Treatment Candidate KVD824; Phase 2 Expected to Initiate in Q2 2021 – – Following Upsized Public Offering, Funded to KVD900 NDA Filing – Cambridge, MA and Salisbury, England, March 11, 2021 – K |
|
| February 16, 2021 |
SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| February 16, 2021 |
SC 13D/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* KALVISTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 483497103 (CUSIP Number) Brent Faduski SVLSF IV, LLC One Boston Place 201 Washington Street, Suite 3900 Boston, MA 02108 (617) 367-8100 (Na |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* KalVista Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 483497103 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| February 11, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 9, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 001-36830 20-0915291 (State or Other Jurisdiction of Incorporation) |
|
| February 11, 2021 |
EX-1.1 Exhibit 1.1 5,375,000 shares KalVista Pharmaceuticals, Inc. UNDERWRITING AGREEMENT February 10, 2021 JEFFERIES LLC STIFEL, NICOLAUS & COMPANY, INCORPORATED CANTOR FITZGERALD & CO. As Representatives of the several Underwriters c/o JEFFERIES LLC 520 Madison Avenue New York, New York 10022 c/o STIFEL, NICOLAUS & COMPANY, INCORPORATED 787 Seventh Avenue New York, New York 10019 c/o CANTOR FITZ |
|
| February 11, 2021 |
EX-99.1 Exhibit 99.1 KalVista Pharmaceuticals Announces Pricing of an Upsized $193.5 Million Public Offering of Common Stock Cambridge, MA & Salisbury, England, February 10, 2021 – KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced the pricing of its upsized underwritten public offering of 5,375,000 shares of its common stock at a price to the public of $36.00 per share. The gross proce |
|
| February 11, 2021 |
5,375,000 Shares KALVISTA PHARMACEUTICALS, INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228831 PROSPECTUS SUPPLEMENT (To Prospectus dated December 21, 2018) 5,375,000 Shares KALVISTA PHARMACEUTICALS, INC. Common Stock We are offering 5,375,000 shares of our common stock, $0.001 par value per share, in this offering. Our common stock is quoted on The Nasdaq Global Market under the symbol “KALV.” On February |
|
| February 10, 2021 |
S-3MEF As filed with the Securities and Exchange Commission on February 10, 2021 Registration No. |
|
| February 9, 2021 |
4,500,000 Shares KALVISTA PHARMACEUTICALS, INC. Common Stock 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-228831 The information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to |
|
| January 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 21, 2021 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Co |
|
| December 18, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (C |
|
| December 10, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (C |
|
| December 10, 2020 |
Exhibit 99.1 KalVista Pharmaceuticals Reports Second Fiscal Quarter Results ? KVD900 Phase 2 Clinical Trial Patient Treatment Completed; Data Expected Q1 2021 ? Cambridge, MA and Salisbury, England, December 10, 2020 ? KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibi |
|
| December 10, 2020 |
Exhibit 10.1 FIRST AMENDMENT OF LEASE This FIRST AMENDMENT OF LEASE (this ?Amendment?) is made as of the 20th day of November, 2020 (the ?Effective Date?), between 55 CAMBRIDGE PARKWAY, LLC, a Delaware limited liability company, having an address c/o Invesco Real Estate, 225 Liberty Street ? 12th floor, New York, New York 10281, as landlord (?Landlord?), and KALVISTA PHARMACEUTICALS, INC., a Delaw |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| December 1, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (C |
|
| November 16, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 16, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation |
|
| October 2, 2020 |
Submission of Matters to a Vote of Security Holders - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Com |
|
| September 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. |
|
| September 14, 2020 |
Exhibit 99.1 KalVista Pharmaceuticals Reports First Fiscal Quarter Results – KVD900 On-Demand Data Expected Q4 2020 – Cambridge, MA and Salisbury, England, September 14, 2020 – KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors, today provided an operational update |
|
| September 14, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) ( |
|
| August 25, 2020 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 2, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 1, 2020 KALVISTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-36830 20-0915291 (State or other jurisdiction of incorporation) (Commis |
|
| July 2, 2020 |
Exhibit 99.1 KalVista Pharmaceuticals Provides Operational Update and Fiscal Year Financial Results – KVD900 Phase 2 Clinical Trial for Oral Treatment of Hereditary Angioedema (HAE) Data Expected in 2H 2020 – – Oral HAE Prophylactic Candidate KVD824 Phase 2 Clinical Trial Planned to Commence in 2H 2020 – – Operations Funded into 2022 – Cambridge, MA and Salisbury, England, July 1, 2020 – KalVista |
